Newell Brands Inc. Stock Slides 5.4%, Underperforms Peers
Dow Jones2026/09/09 20:34This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Newell Brands Inc. shed 5.4% to $6.00 on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.5% to 7,636.36 and Dow Jones Industrial Average falling 0.8% to 52,380.66.
The stock's fall snapped a four-day winning streak.
Newell Brands Inc. closed 15.8% short of its 52-week high of $7.13, which the company achieved on July 31st.
The stock underperformed when compared to some of its peers, as Procter & Gamble Co. fell 2.0% to $142.64, Clorox Co. fell 2.2% to $89.62, and Avery Dennison Corp. fell 0.53% to $169.79.
Trading volume totaled 7.6 million, compared to the 50-day average of 9.1 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 09, 2026 16:34 ET (20:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Crypto prices
More
